Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.76% |
| 2 | Technology | 16.41% |
| 3 | Consumer Staples | 10.58% |
| 4 | Consumer Discretionary | 10.13% |
| 5 | Communication Services | 9.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MMX
2026
DELISTED
Maverix Metals Inc. Common Shares
MMX
| $2.6M | ﹤0.01% |
583,700
+204,000
| +54% | +$877K |
|
2027
Landmark Bancorp
LARK
$196M
| $2.6M | ﹤0.01% |
140,765
+16,243
| +13% | +$283K |
|
2028
Innovative Solutions & Support
ISSC
$412M
| $2.6M | ﹤0.01% |
519,010
-10,490
| -2% | -$46.1K |
|
|
INDT
2029
DELISTED
INDUS Realty Trust, Inc. (MD) Common Stock
INDT
| $2.6M | ﹤0.01% |
47,897
-6,365
| -12% | -$264K |
|
2030
Minerva Neurosciences
NERV
$219M
| $2.59M | ﹤0.01% |
89,688
+1,675
| +2% | +$98.3K |
|
2031
Marten Transport
MRTN
$1.24B
| $2.59M | ﹤0.01% |
+154,350
| New | +$2.42M |
|
2032
Associated Banc-Corp
ASB
$6.11B
| $2.59M | ﹤0.01% |
189,131
-328,000
| -63% | -$4.46M |
|
|
CWBC
2033
Community West Bancshares
CWBC
$708M
| $2.58M | ﹤0.01% |
167,881
-21,000
| -11% | -$291K |
|
2034
SIGA Technologies
SIGA
$216M
| $2.58M | ﹤0.01% |
437,014
+254,502
| +139% | +$1.45M |
|
|
CAMP
2035
DELISTED
CalAmp Corp.
CAMP
| $2.58M | ﹤0.01% |
14,017
-18,831
| -57% | -$2.91M |
|
2036
iShares Core S&P Mid-Cap ETF
IJH
$129B
| $2.58M | ﹤0.01% |
72,500
+50,000
| +222% | +$1.66M |
|
2037
Quad
QUAD
$513M
| $2.57M | ﹤0.01% |
791,400
+203,700
| +35% | +$624K |
|
2038
Imunon
IMNN
$6.93M
| $2.56M | ﹤0.01% |
3,513
+2,711
| +338% | +$1.18M |
|
|
SCPX
2039
DELISTED
Scorpius Holdings, Inc.
SCPX
| $2.56M | ﹤0.01% |
108
+44
| +69% | +$853K |
|
|
SWI
2040
DELISTED
SolarWinds Corporation Common Stock
SWI
| $2.56M | ﹤0.01% |
+137,081
| New | +$2.53M |
|
|
MOR
2041
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $2.55M | ﹤0.01% |
80,600
+18,767
| +30% | +$547K |
|
2042
Boston Omaha
BOC
$421M
| $2.54M | ﹤0.01% |
159,000
+121,100
| +320% | +$2.02M |
|
2043
Krystal Biotech
KRYS
$9.83B
| $2.54M | ﹤0.01% |
61,400
+55,400
| +923% | +$2.67M |
|
|
RTL
2044
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
| $2.54M | ﹤0.01% |
320,433
-261,673
| -45% | -$1.92M |
|
2045
GFL Environmental
GFL
$15.1B
| $2.54M | ﹤0.01% |
+135,200
| New | +$2.31M |
|
2046
Republic Bancorp
RBCAA
$1.92B
| $2.54M | ﹤0.01% |
77,600
-28,700
| -27% | -$907K |
|
2047
Townsquare Media
TSQ
$104M
| $2.54M | ﹤0.01% |
567,652
+9,215
| +2% | +$42.2K |
|
|
TPC
2048
Tutor Perini Cor
TPC
$5.09B
| $2.54M | ﹤0.01% |
+208,280
| New | +$1.86M |
|
2049
Renasant Corp
RNST
$3.98B
| $2.54M | ﹤0.01% |
101,839
-188,700
| -65% | -$4.48M |
|
|
NOTV
2050
DELISTED
Inotiv
NOTV
| $2.52M | ﹤0.01% |
503,406
+21,602
| +4% | +$99.4K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 26% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.